Simulations Plus, Inc. (SLP)
Healthcare · NMS
Price as at 1 Oct 2026, 01:34 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Simulations Plus, Inc. trades at $18.43, which is 57% above the $7.90 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 51 out of 100, which is a moat, but not a deep one. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 45.6 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
SLP dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2024 | $0.180 | 3 |
| 2023 | $0.240 | 4 |
| 2022 | $0.240 | 4 |
| 2021 | $0.240 | 4 |
| 2020 | $0.240 | 4 |
| 2019 | $0.240 | 4 |
| 2018 | $0.240 | 4 |
| 2017 | $0.210 | 4 |
| 2016 | $0.200 | 4 |
| 2015 | $0.200 | 4 |
| 2014 | $0.200 | 4 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
SLP earnings and analyst estimates
Recommendation mix, 5 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
SLP passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- First Eagle, First Eagle Investment Management, LLC$19.60M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$7.52M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$5.50M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$3.39M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$3.36M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
SLP peers
The largest companies in the same industry (Health Information Services), then in the same sector.
- PME.AX Pro Medicus Limited
- HNGE Hinge Health, Inc.
- WAY Waystar Holding Corp.
- PRVA Privia Health Group, Inc.
- HTFL Heartflow, Inc.
- OMCL Omnicell, Inc.
- CERT Certara, Inc.
- TALK Talkspace, Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Simulations Plus, Inc. (SLP) undervalued?
Against our fair value estimate of $7.90, SLP at $18.43 is 57% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own SLP?
9 of the institutions we track reported a position in SLP in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is SLP's P/E ratio?
SLP trades at 45.6 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Where does SteadyShares get its SLP data?
Fundamentals for SLP come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:34 UTC and is delayed. Our data quality score for this company is 92/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for SLP, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.